EXS-617 is under clinical development by Exscientia and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData, Phase II drugs for Non-Small Cell Lung Cancer have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how EXS-617’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
EXS-617 overview
EXS-617 is under development for the treatment of advanced solid tumors like epithelial ovarian carcinoma, head and neck squamous cell carcinoma, colorectal cancer, pancreatic cancer, non-small cell lung cancer (NSCLC), HR+/HER2- breast carcinoma and triple-negative breast cancer (TNBC). It is administered through oral route The drug candidate acts by targeting cyclin-dependent kinase 7 (CDK7).
Exscientia overview
Exscientia is an artificial intelligence-driven pharma tech company committed to discovering, designing, and developing drugs. The Company’s AI process is comprised of five elements, including precision target, precision design, precision experiment, precision medicine and presentations and publications. The company internal pipeline includes wholly owned programmes, majority owned programmes and co-owned programmes and this focuses on oncology, immuno-oncology and antivirals. These initiatives include EXS21546, a pilot immuno-oncology asset that we hold a majority of, GTAEXS617, a co-owned oncology asset, and EXS73565 and EXS74539. Exscientia is headquartered in Oxford, the UK.
For a complete picture of EXS-617’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
